---
layout: default
title: Fulvestrant
parent: Model Prediction Only (L5)
nav_order: 417
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fulvestrant: From Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

Fulvestrant is an estrogen-receptor-targeting drug used in hormone receptor-positive breast cancer. The TxGNN model predicts it may be effective for **HIV infectious disease**, but this is a graph-based prediction only. There are **0 related clinical trials** and **1 publication**, and that publication concerns HTLV-1, not HIV.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Canadian licence records provided. Fulvestrant is known as an ER-positive breast cancer therapy, and all trials retrieved for this drug are in breast cancer. |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 6 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fulvestrant is a selective estrogen receptor degrader (SERD) used in breast cancer. No antiviral or immunomodulatory mechanism against HIV has been established for it.

The very high score (0.999) reflects the drug's position in the knowledge graph, not biological evidence. Several other top-ranked predictions are retroviral or immunodeficiency entries: feline AIDS, simian immunodeficiency virus infection, and HIV. This pattern suggests a shared graph neighbourhood rather than a real therapeutic link. We found no credible mechanistic connection between estrogen receptor degradation and HIV.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Multi-cohort omics study | Research Square | Cross-omics analysis of disease mechanisms and therapeutic targets in HTLV-1-associated myelopathy. This is a different retrovirus and disease, not HIV, so it does not support the prediction. |

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2483610 | FULVESTRANT INJECTION |
| 2530635 | FULVESTRANT INJECTABLE |
| 2248624 | FASLODEX |
| 2460130 | TEVA-FULVESTRANT INJECTION |
| 2558971 | FULVESTRANT INJECTION |

The records provided do not include dosage form or approved indication text for these products. Six licences are recorded in total; five are listed above.

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted endocrine therapy (selective estrogen receptor degrader), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV prediction rests on the model score alone. There are no trials, no relevant literature, and no plausible mechanism. The one publication retrieved concerns HTLV-1, a different retrovirus and disease. Other model outputs for this drug are also weak. The "multiple endocrine neoplasia" trial hits are all breast cancer studies and look like a disease-name mapping error. Rheumatoid arthritis has some preclinical estrogen-signalling literature, but its direction of effect is inconsistent and no clinical evidence exists.

**To proceed, the following is needed:**
- Mechanism of action data (DrugBank), to assess any link to HIV biology
- Health Canada package insert warnings and contraindications, which are needed before any safety screening
- Original indication and approved indication text for the Canadian licences
- Preclinical or in vitro evidence that estrogen receptor degradation affects HIV replication or pathogenesis
- A check of the disease-name mapping in the source data, given the suspected false match for multiple endocrine neoplasia
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

